CN Patent

CN110156671A — 新型的索拉非尼共晶及其制备方法

Assigned to Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd · Expires 2019-08-23 · 7y expired

What this patent protects

本发明涉及一种索拉非尼2‑氨基嘧啶共晶A及其制备方法。该晶型制备工艺简单，有利于提高批次重现性，保证了其在原料或制剂制备过程中的稳定性。并且，本发明提供的索拉非尼2‑氨基嘧啶共晶A室温稳定性好，便于长期贮存和运输，保证了药品质量和用药安全。

USPTO Abstract

本发明涉及一种索拉非尼2‑氨基嘧啶共晶A及其制备方法。该晶型制备工艺简单，有利于提高批次重现性，保证了其在原料或制剂制备过程中的稳定性。并且，本发明提供的索拉非尼2‑氨基嘧啶共晶A室温稳定性好，便于长期贮存和运输，保证了药品质量和用药安全。

Drugs covered by this patent

Patent Metadata

Patent number
CN110156671A
Jurisdiction
CN
Classification
—
Expires
2019-08-23
Drug substance claim
No
Drug product claim
No
Assignee
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.